Heptares granted patents covering stabilised receptor technology in Europe and Japan
Key patent grants protect Heptares’ leading position in GPCR-targeted drug design and discovery
Heptares Therapeutics announced that the first of a series of patent applications covering its methods for generating G-protein coupled receptors (GPCR) with increased conformational stability (StaR® technology) has resulted in patents being granted in Europe (EP2121919) and Japan (JP4842400). This patent family is also pending in the United States and in other territories worldwide.
This patent family broadly covers methods for transforming GPCRs, which are highly unstable when removed from cellular membranes, into stabilised forms (StaRs®) corresponding to selected pharmacologically relevant conformations using any method of mutagenesis, expression or assay. The unique properties of StaRs® have enabled Heptares to build a powerful and integrated platform designed to exploit, for the first time, the full range of structure-based approaches for drug discovery. Using this approach, the Company is building a pipeline of first-in-class and best-in-class GPCR-targeted medicines, with a focus on CNS and metabolic indications.
Most read news
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.